Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): A meta-analysis of individual data from 1764 patients

Annals of Oncology

Volumn 17, Issue 3, 2006, Pages 473-483

  Auperin A ^a   Le Pechoux C ^a   Pignon, J P ^a   Koning, C ^b   Jeremic, B ^c   Clamon, G ^d   Einhorn, L ^e   Ball, D ^f   Trovo, M G ^g   Groen, H J M ^h   Bonner, J A ⁱ   Le Chevalier, T ^a   Arriagada, R ^a,j  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c University Hospital   (Serbia)

^d UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^e INDIANA UNIVERSITY   (United States)

^f PETER MACCALLUM CANCER CENTRE   (Australia)

^g CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^h UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

ⁱ UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^j The Faculté de Médecine Paris XI   (Serbia)

more..

Author keywords

Concomitant radio chemotherapy; Individual patient data; Locally advanced non small cell lung cancer; Meta analysis; Randomised trial; Systematic review

Indexed keywords

CARBOPLATIN; CISPLATIN; ETOPOSIDE;

ACCURACY; ADVANCED CANCER; AGE DISTRIBUTION; ARTICLE; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; FOLLOW UP; FUNCTIONAL ASSESSMENT; HUMAN; LUNG NON SMALL CELL CANCER; META ANALYSIS; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SEX DIFFERENCE; SURVIVAL RATE; SURVIVAL TIME; SYSTEMATIC REVIEW; WEIGHT REDUCTION;

EID: 33644666024     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdj117     Document Type: Article

References (43)

1. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide, Version 2.0. IARC CancerBase No5. Lyon, IARCPress 2004.
2. Jemal A, Tiwari RC, Murray T et al. Cancer Statistics, 2004. CA Cancer J Clin 2004; 54: 8-29.
3. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J 1995; 311: 899-909.
4. Soresi E, Clerici M, Grilli R et al. A randomised clinical trial comparing radiation therapy versus radiation therapy plus cis-Dichlorodiamine Platinum (II) in the treatment of locally advanced non-small cell lung cancer. Sem Oncol 1988; 15 (suppl 7): 20-25.
5. Schaake-Koning C, Van Den Bogaert W, Dalesio O et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small cell lung cancer. N Engl J Med 1992; 326: 524-530.
6. Blanke C, Ansari R, Mantravadi R et al. Phase III trial of thoracic irradiation with or without cisplatin for locally advanced unresectable non-small cell lung cancer: A Hoosier Oncology Group Protocol. J Clin Oncol 1995; 13: 1425-1429.
7. Trovo MG, Minatel E, Franchin G et al. Radiotherapy versus radiotherapy enhanced by cisplatin in stage III non-small cell lung cancer. Int J Radiat Oncol Biol Phys 1992; 24: 11-15.
8. Jeremic B, Shibamoto Y, Acimovic L, Djuric L. Randomised trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small cell lung cancer. J Clin Oncol 1995; 13: 452-458.
9. Ball D, Bishop J, Smith J et al. A randomised phase III study of accelerated or standard fraction radiotherapy with or without concurrent carboplatin in inoperable non-small cell lung cancer: Final report of an Australian multi-centre trial. Radiother Oncol 1999; 52: 129-136.
10. Jeremic B, Shibamoto Y, Acimovic L, Milisavljevic S. Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/ etoposide for non-small cell lung cancer: A randomised study. J Clin Oncol 1996; 14: 1065-1070.
11. Clamon G, Herndon J, Cooper R et al. Radiosensitization with carboplatin for patients with unresectable stage III non-small cell lung cancer: A phase III trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group. J Clin Oncol 1999; 17: 4-11.
12. Bonner JA, McGinnis WL, Stella PJ et al. The possible advantage of hyperfractionated thoracic radiotherapy in the treatment of locally advanced non-small cell lung cancer. Results of a North Central Cancer Treatment Group phase III study. Cancer 1998; 82: 1037-1048.
13. Groen HJM, van der Leest AHW, Fokkema E et al. Continuously infused carboplatin used as radiosensitizer in locally unresectable non-small cell lung cancer: A multicenter phase III study. Ann Oncol 2004; 5: 427-432.
14. Rodriguez A, Martin G, del Barco E et al. Locally advanced non-small cell lung cancer treated with chemotherapy and sequential radiotherapy vs chemotherapy followed by concomitant radiotherapy and daily cisplatin. Ann Oncol 2000; 11(Suppl 4): 119 (abstract).
15. Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Controlled Clinical Trials 1996; 17: 343-346.
16. Early Breast Cancer Trialists' Collaborative Group. Treatment of early breast cancer. Vol 1. Worldwide evidence 1985-1990: A systematic overview of all available randomised trials of adjuvant endocrine and cytotoxic therapy. Oxford, UK: Oxford University Press, 1990.
17. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. Br Med J 2003; 327: 557-560.
18. Stewart LA, Parmar MKB. Meta-analysis of the literature or of individual patient data: Is there a difference? Lancet 1993; 341: 418-422.
19. Sedrakyan A, van Der Meulen J, O'Byrne K et al. Postoperative chemotherapy for non-small cell lung cancer: A systematic review and meta-analysis. J Thorac Cardiovasc Surg 2004; 128: 414-9.
20. Hotta K, Matsuo K, Ueoka H et al. Role of adjuvant chemotherapy in patients with resected non-small cell lung cancer: Reappraisal with a meta-analysis of randomized controlled trials. J Clin Oncol 2004; 22: 3860-7.
21. Berghmans T, Paesmans M, Meert AP et al. Survival improvement in resectable non-small cell lung cancer with (neo)adjuvant chemotherapy: results of a meta-analysis of the literature. Lung Cancer 2005; 49: 13-23.
22. Hamada C, Tanaka F, Ohta M et al. Meta-analysis of postoperative adjuvant chemotherapy with Tegafur-Uracil in non-small-cell lung cancer. J Clin Oncol 2005; 23: 4999-5006.
23. Marino P, Preatoni A, Cantoni A. Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb nonsmall cell lung cancer. A meta-analysis. Cancer 1995; 76: 593-601.
24. Pritchard RS, Anthony SP. Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, Non-Small-Cell Lung Cancer. A meta-analysis. Ann Intern Med 1996; 125: 723-729.
25. Rakovitch E, Tsao M, Ung Y et al. Comparison of the efficacy and acute toxicity of weekly versus daily chemoradiotherapy for non-small cell lung cancer: A meta-analysis. Int J Radiat Oncol Biol Phys 2004; 58: 196-203.
26. Rowell NP, O'Rourke NP. Concurrent chemoradiotherapy in non-small cell lung cancer. The Cochrane Database of Systematic Reviews 2004, Issue 4. Art. No.: CD002140.pub2. DOI: 10.1002/14651858.CD002140.pub2.
27. Duchateau L, Pignon JP, Bijnens L et al. Individual patient- versus literature-based meta-analysis of survival data: Time to event and event rate at a particular time can make a difference, an example based on head and neck cancer. Control Clin Trials 2001; 22: 538-547.
28. Gervais R, Ducolone A, Le Chevalier T et al. Conventional radiation with daily carboplatin compared to radiation alone after induction chemotherapy [vinorelbine-cisplatin]: Final results of a randomized phase III trial in stage III unresectable non small cell lung cancer. Study CRG/BMS/NPC/96 of the French Lung Cancer Study Group FNCLCC and IFCT. Proc Am Soc Clin Oncol 2005; 24: 625s (Abstr).
29. Arriagada R, Le Chevalier T, Quoix E et al. Effect of chemotherapy on locally advanced non-small cell lung carcinoma: A randomised study of 353 patients. GETCB (Groupe d'Etude et Traitement des Cancers Bronchiques), FNCLCC (Federation Nationale des Centres de Lutte contre le Cancer) and the CEBI trialists. Int J Radiat Oncol Biol Phys 1991; 20: 1183-1190.
30. Le Chevalier T, Arriagada R, Quoix et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small cell lung cancer: First analysis of a randomised trial in 353 patients. J Natl Cancer Inst 1991; 83: 417-423.
31. Komaki R, Scott CB, Sause WT et al. Induction cisplatin/vinblastine and irradiation vs. irradiation in unresectable squamous cell lung cancer: failure patterns by cell type in RTOG 88-08/ECOG 4588. Radiation Therapy Oncology Group. Eastern Cooperative Oncology Group. Int J Radiat Oncol Biol Phys 1997; 39: 537-544.
32. Furuse K, Fukuoka KM, Takada Y et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine and cisplatin in unresectable stage III non-small cell lung cancer. J Clin Oncol 1999; 17: 2692-2699.
33. Zatloukal PV, Petruzelka L, Zemanova M et al. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer. a randomised study. Lung Cancer 2004; 46: 87-98.
34. Curran W, Scott CB, Langer CJ et al. Long-term benefit is observed in a phase III comparison of sequential vs. concurrent chemo-radiation for patients with unresected stage III NSCLC: RTOG 9410. Proc Am Soc Clin Oncol 2003; 22: 621 (Abstr).
35. Vokes EE, Herndon JE, Kelley MJ et al. Cancer and Leukemia Group B. Induction chemotherapy followed by concomitant chemoradiotherapy (CT/ XRT) versus CT/XRT alone for regionally advanced unresectable non-small cell lung cancer: Initial analysis of a randomized phase III trial. Proc Am Soc Clin Oncol 2004; 23: 7005 (Abstr).
36. Burdett S, Stewart L, Auperin A, Pignon JP. Chemotherapy in non-small cell lung cancer: An update of an individual patient data meta-analysis. J Clin Oncol 2005; 23: 924-925.
37. Wozniak AJ, Crowley JJ, Balcerzak SP et al. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small cell lung cancer: A Southwest Oncology Group study. J Clin Oncol 1998; 16: 2459-2465.
38. Sandler AB, Nemunaitis J, Denham C et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small cell lung cancer. J Clin Oncol 2000; 18: 122-130.
39. Gatzemeier U, von Pawel J, Gottfried M et al. Phase III comparative study of high dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small cell lung cancer. J Clin Oncol 2000; 18: 3390-3399.
40. Delbaldo C, Michiels S, Syz N et al. Benefits of adding one drug to a single-agent or a two-agent chemotherapy regimen in advanced non-small cell lung cancer (NSCLC). A meta-analysis. JAMA 2004; 292: 470-484.
41. Schild SE, Stella PJ, Geyer SM et al. The outcome of combined-modality therapy for stage III non-small cell lung cancer in the elderly. J Clin Oncol 2003; 21: 3201-3206.
42. Langer CJ, Manola J, Bernardo P et al. Cisplatin-based therapy for elderly patients with advanced non-small cell lung cancer: Implications of Eastern Cooperative Oncology Group 5592, a randomised trial. J Natl Cancer Inst 2002; 94: 173-181.
43. Rocha Lima CMS, Herndon JE, Kosty M et al. Therapy choices among older patients with lung carcinoma. An evaluation of two trials of the Cancer and Leukemia Group B. Cancer 2002; 94: 181-187.